 Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | | The end of the list has been reached or no journals were found for your choice. |
|
|
- Importance of randomisation--a call to researchers
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Wiffen; P.
Pages: 99 - 99
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2025-004501
Issue No: Vol. 32, No. 2 (2025)
- Contribution of hospital pharmacists to sustainable healthcare: a
systematic review-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Pitard, M; Rouviere, N, Leguelinel-Blache, G, Chasseigne, V.
Pages: 100 - 105
Abstract: BackgroundWith a global annual carbon footprint of the healthcare sector of 2 gigatons of CO2e, healthcare systems must contribute to the fight against climate change. Hospital pharmacists could be key players in ecological transition due to their role in managing healthcare products. The aim of this study was to summarise the evidence on interventions implemented in healthcare facilities involving pharmacists to improve the environmental footprint of healthcare.MethodsThis systematic review was conducted following PRISMA 2020 guidelines. The Medline, Web of Science and ScienceDirect databases were searched for studies published between 2013 and 2023. To be eligible for inclusion, studies had to include hospital pharmacists and present contributions aimed at reducing the environmental footprint of healthcare in healthcare facilities. Outcomes were the description of the contribution, the methods used and the stages of healthcare product lifecycle analysed. A Mixed Methods Appraisal Tool was used to assess the risk of bias for each study.ResultsSeventeen studies were included. Pharmacists played a leading role in 15 (88%) and had a supporting role in the others. The healthcare products targeted were medicines (59%), medical devices (12%) or both (29%). The stages of the healthcare product cycle addressed by the contributions were elimination (71%), dispensing (35%), procurement and supply (35%), production (29%), and prescription (24%). Only two studies used life cycle assessment and only one assessed all three pillars of sustainability. Two studies had good methodological quality while the rest had at least one element of uncertainty.ConclusionThis review confirms the central role of the pharmacist and the importance of a multidisciplinary approach in implementing eco-responsible actions. It could be useful to hospitals and other teams wanting to improve sustainable actions and it emphasises the importance of collaborating with pharmacists when planning sustainable initiatives. Future eco-responsible initiatives must use robust reproducible methods.Trial registrationPROSPERO #CRD42023406835
Keywords:
Editor''s choice
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2024-004098
Issue No: Vol. 32, No. 2 (2025)
- Development of hospital pharmacy services at transition of care points: a
scoping review-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Stoll, J. T; Weidmann, A. E.
Pages: 106 - 112
Abstract: BackgroundSeveral hospital pharmacy services exist, which take place at different interfaces of patient care. Although they are an important tool for improving medication safety, they are not yet sufficiently implemented in hospitals around the world.ObjectiveThis scoping review aims to summarise different hospital pharmacy services at transition of care (TOC) points in order to identify development trends and practice patterns in high-income countries over the past decade.MethodsA literature search of four databases (PubMed, PubPharm, Cochrane Library (Ovid) and ScienceDirect) since 2011 was conducted. A detailed search strategy was developed and refined with the help of a research librarian. Title, abstract and full-text selection was carried out by two researchers independently. The study was reported in accordance with the PRISMA-ScR items to ensure quality standard reporting. Only studies originating from developed countries and published in the English language were included. The data obtained were extracted and summarised using a data extraction form developed to meet the research aims of the study.ResultsOf the 5456 search results, 65 studies met the inclusion criteria. These originated from Europe (n=29), North America/Canada (n=28), Australia (n=7) and Asia (n=1). Individual TOC services such as medication reconciliation and medication review on admission and at discharge were the main focus of published literature practice patterns between 2011 and 2016, after which a more holistic TOC service started to emerge that follows patients across all TOC points during their hospital stay. Facilitators and barriers were consistently dependent on resources and infrastructure. Clinical and economic outcomes show a mixed picture.ConclusionDuring the past decade pharmaceutical services have developed more holistic TOC services. Large-scale high-quality studies are needed to reliably determine clinical and economic benefit.
Keywords:
EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2023-003836
Issue No: Vol. 32, No. 2 (2025)
- Medication safety strategies in European adult, paediatric, and neonatal
intensive care units: a cross-sectional survey-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Abdelaziz, S; Amigoni, A, Kurttila, M, Laaksonen, R, Silvari, V, Franklin, B. D.
Pages: 113 - 120
Abstract: ObjectivesPatients in intensive care units (ICUs) are potentially more vulnerable to medication errors than patients admitted to general wards. However, little is known about medication safety strategies used in European ICUs. Our objectives were to explore the strategies being used and being planned within European ICUs, to identify areas of variation, and to inform recommendations to improve medication safety in this patient group.MethodsWe distributed an online survey, in seven European languages, via professional networks and social media. The survey explored a range of medication safety strategies and whether they were in use (and if so, whether fully or partially implemented) or being planned. Demographic information about respondents and their ICUs was also captured. A descriptive analysis was conducted, which included exploring geographical variation.ResultsWe obtained 587 valid responses from 32 different countries, with 317 (54%) completed by pharmacy staff. Medication safety practices most commonly implemented were patients’ allergies being visible for all staff involved in their care (fully implemented in 382 (65%) of respondents’ ICUs), standardised emergency medication stored in a fixed place (337, 57%), and use of standardised medication concentrations for commonly used intravenous infusions (330, 56%). Electronic prescribing systems were fully implemented in 310 (53%). A pharmacist was reported to be fully implemented in 181 (31%) of ICUs, of which there was 126 (70%) where there was a pharmacist review of all ordered medication five days per week. Critical care pharmacists were most common in Northern European ICUs (fully implemented to ICUs in 102, 50%) and electronic prescribing in Western Europe (108, 65%).ConclusionsThere is considerable variation in medication safety strategies used within European ICUs, both between and within geographical areas. Our findings may be helpful to ICU staff in identifying strategies that should be considered for implementation.
Keywords:
EAHP Statement 5: Patient Safety and Quality Assurance
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2023-004018
Issue No: Vol. 32, No. 2 (2025)
- Risk assessment of clinical trial protocols: a tool for hospital
pharmacists to reduce human error in experimental drug management-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Cancellieri, G; Provenzani, A, Polidori, C, Polidori, P.
Pages: 121 - 125
Abstract: Background and objectivesHospital pharmacists collaborate in clinical trials by managing the reception, conservation, distribution, return and destruction of the investigational medical products (IMP). However, errors can happen during the simultaneous management of multiple trials because each clinical trial stipulates its own method for managing the drug under study. In order to promote optimal management by hospital pharmacists, we developed a method for calculating a risk of error index for each experimental protocol, and wrote standard procedures for managing trials assigned low, moderate and high risk levels, to provide hospital pharmacists with a systematic tool for reducing human error in the management of IMPs for multiple clinical trials.MethodsCalculation of this risk of error index () entails four factors: the pharmacological risk of error () inherent in the pharmacological characteristics and route of administration of the IMP (carcinogenic, mutagenic, cytotoxic nature of the drug, parental or non-parenteral administration), the technological risk of error (α) involved should drug compounding be required, the risk of error related to the number of patients enrolled (np) and the risk of error intrinsic to the protocol () when it involves placebos, randomisation or other factors. We developed the formula to define trials as low (
Keywords:
EAHP Statement 5: Patient Safety and Quality Assurance
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2024-004154
Issue No: Vol. 32, No. 2 (2025)
- Impact of pharmaceutical care on hospital readmissions for heart failure:
a randomised trial-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Montero-Llorente, B; Perez Menendez-Conde, C, Gonzalez Ferrer, E, Lopez Castellanos, G. T, Bedoya del Olmo, L. M, Bermejo Vicedo, T.
Pages: 126 - 131
Abstract: ObjectivesTo evaluate the impact of pharmaceutical care on the number of readmissions and visits to the emergency department due to heart failure 30 days after hospital discharge, based on a programme of continuous pharmaceutical care throughout the care process, and to assess the differences between the control and intervention groups at 90 days after discharge (number of readmissions and visits to the emergency department, time from discharge to new readmission or visit to the emergency department).MethodsA single-centre experimental longitudinal prospective open and parallel-group study with balanced randomisation (1:1) was carried out in a tertiary hospital in Spain. Patients with a diagnosis of primary or decompensated heart failure admitted to the Cardiology Service or the Heart Failure and Vascular Risk Unit were recruited between March 2019 and November 2021 and randomly assigned, using a randomised block model, to the control (standard care) or intervention (continuing care model) groups. Epidemiological, clinical and pharmacology data were recorded. As a measure of association, we used the mean difference and the Student’s t-test. A p value of
Keywords:
EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2024-004218
Issue No: Vol. 32, No. 2 (2025)
- Feasibility study of the digital tool Max for the patient-provided
medication list in the medication reconciliation process prior to
hospitalisation: patient willingness and usability, time saved and
reliability-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Nardone, P; Nicolay, S, Pouget, A.-M, Civade, E, Strumia, M, Rouzaud, C. L.
Pages: 132 - 136
Abstract: PurposeMore than 20% of prescription errors in hospitals are due to an incomplete medication history. Medication reconciliation is a solution to decrease unintentional discrepancies between medications taken at home and hospital prescriptions. It is a normalised clinical activity but it is time consuming. Medication reconciliation usually uses three sources of information for an optimised medical synthesis, one of which is the patient. A conversational robot for patients could be a solution to assist. Numerous digital applications are designed for patients and need to be tested for usability, satisfaction, reliability and time saved.MethodWe analysed Max, a conversational robot for patients scheduled for surgery in Toulouse University Hospital, using routinely collected health data in three successive steps. We examined willingness, compliance and patient satisfaction of usability with a Likert questionnaire and measured the time spent with Max and without. Finally, the reliability has been explored.ResultsThe three successive observational steps were assessment of willingness and compliance (79 patients), time saved (61 patients) and reliability of the tool (68 patients). 71% agreed to use Max after a telephone call but only 73% of patients completed Max entirely. Max was well received and the overall satisfaction of usability was high for ease of use, readability, relevance and number of questions. Max saved a few minutes by optimised medical synthesis compared with a conventional telephone call. However, the reliability appeared to be lower than the human conventional telephone call. Randomised controlled trials are needed to confirm this feasibility study.ConclusionMax was appreciated by patients and appeared to be suitable for assisting pharmacists in medication reconciliation. The tool established the list of treatments taken by the patient at home but reliability appeared to be lower than a conventional telephone call, recommending a ‘double check’ on the patient’s arrival.
Keywords:
EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2024-004293
Issue No: Vol. 32, No. 2 (2025)
- Older people, medication usage and long-term care pharmacists: a
retrospective cohort study-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Goncalves, J. R; Sleath, B. L, Cerdeira, M, Cavaco, A. M.
Pages: 137 - 142
Abstract: ObjectiveTo investigate the impact of the presence of a pharmacist on medication usage in long-term care facilities.MethodsThe study followed a retrospective cohort design, with a sample of patients aged ≥65 years admitted to three long-term care facilities over 30 months. Data on age, gender, type of stay, the presence or absence of a pharmacist and pharmacotherapeutic profile at admission and discharge were obtained for study patients. Variations in the number of medicines, anticholinergic burden and potentially inappropriate medications at admission and discharge were assessed as outcome variables. Anticholinergic burden and potentially inappropriate medications were assessed using the Anticholinergic Cognitive Burden scale and the EU(7)-PIM List, respectively. One-sample t-tests were used to compare the mean values of the outcome variables. A four-way ANOVA was used to test the association between background and outcome variables. Partial eta squared (2) was used to measure the effect size.ResultsA total of 1366 patients were studied. All outcome variables showed a statistically significant increase at discharge compared with admission. The presence of a pharmacist was statistically significant in improving the number of medicines (p
Keywords:
EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2023-003908
Issue No: Vol. 32, No. 2 (2025)
- Assessment of the accuracy of estimated free phenytoin concentrations in a
mixed patient population-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Horton, N. S; Hanton, S. L, Sheppard, L, Birch, K, Chadwick, C. A.
Pages: 143 - 148
Abstract: ObjectivesPhenytoin is an anti-epileptic drug that has a narrow therapeutic index, and therefore requires therapeutic drug monitoring. Only the free fraction is pharmacologically active, and in some cases, accurate determination of the free phenytoin concentration may be essential to prevent phenytoin toxicity. Although it is possible to measure free phenytoin concentration, often only the total concentration is measured, with equations used to estimate the free fraction. Several equations are quoted in the literature with no overall consensus with regard to accuracy. This study aimed to assess the correlation between total and free phenytoin in a mixed patient population, and to compare the accuracy of several different equations used to estimate the free phenytoin concentration.MethodsFifty-one serum samples were analysed for total phenytoin, free phenytoin and albumin. The measured free phenytoin concentrations were compared against those estimated using five selected equations, identified through a literature search.ResultsThis study showed poor correlation between the total and measured free phenytoin concentrations, and between the estimated and measured free concentrations. The overall correlation was concentration-dependent, but a correction factor could not be applied to improve the accuracy consistently. The equations assessed showed wide variability between the estimated and measured free phenytoin concentrations, with several showing a clinically significant negative bias when compared with the measured free fraction.DiscussionThis study highlights the disparity of the free phenytoin concentrations generated by the equations. Underestimation of free phenytoin concentrations using these equations may result in phenytoin toxicity, bringing into question the safety of using calculated values for patient management in place of physical measurement of free phenytoin concentration by ultra-performance liquid chromatography tandem mass spectrometry.
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2023-003878
Issue No: Vol. 32, No. 2 (2025)
- Physical compatibility of lipid emulsions and intravenous medications used
in neonatal intensive care settings-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Senarathna, S. M. D. K. G; Strunk, T, Petrovski, M, Woodland, S, Martinez, J, Chuang, V. T. G, Batty, K. T.
Pages: 149 - 153
Abstract: ObjectiveThe purpose of this study was to investigate the physical compatibility of intravenous lipid emulsions with parenteral medications used in neonatal intensive care.MethodsLipid emulsion and drug solutions were combined 1:1 in glass vials, inspected for physical incompatibility at 0, 1 and 2 hours, and assessed on the basis of lipid droplet size at 0 and 2 hours after mixing. Intravenous fluid controls (Water for Injection, sodium chloride 0.9% w/v, glucose 5% w/v), positive controls (gentamicin, albumin), negative controls (metronidazole, paracetamol, vancomycin) and 21 previously untested drug combinations were evaluated.ResultsNo phase separation, change in colour, gas production or other visible anomaly was observed. The between-run mean droplet diameter (MDD) for SMOFlipid20% alone (0.301±0.008 µm) was comparable to the lipid emulsion/intravenous fluid and lipid emulsion/drug solution combinations. In addition to gentamicin and albumin, caffeine citrate (20 mg/mL) was shown to be incompatible with the lipid emulsion. All other lipid:drug combinations were compatible, based on the MDD data.ConclusionIntravenous lipid emulsions were found to be compatible with 20 parenteral medications, including antimicrobial agents, inotropes, anti-inflammatory drugs and caffeine base, in simulated Y-site conditions. The lipid emulsion was incompatible with caffeine citrate injection.
Keywords:
EAHP Statement 3: Production and Compounding
PubDate: 2025-02-21T00:45:40-08:00
DOI: 10.1136/ejhpharm-2023-003870
Issue No: Vol. 32, No. 2 (2025)
- In-use stability of ready-to-administer daratumumab subcutaneous injection
solution in plastic syringes-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Knoll, L; Thiesen, J, Klassen, M. D, Reinders, L. M. H, Tuerk, J, Kraemer, I.
Pages: 154 - 160
Abstract: ObjectiveIn multiple myeloma patients, daratumumab is preferably injected subcutaneously. The summary of product characteristics of daratumumab subcutaneous injection solution specifies physicochemical stability for the prepared syringe for 24 hours at 2–8°C protected from light, and another 12 hours at room temperature (15–25°C) in ambient light conditions. The aim of this study was to determine the in-use stability of ready-to-administer daratumumab subcutaneous injection solution in different types of syringe and different conditions over a 28-day period.MethodsDaratumumab subcutaneous (DARZALEX 1800 mg) injection solution was withdrawn into disposable three-piece Luer-Lock syringes (20 mL, 50 mL), capped, and stored light protected at 2–8°C or at room temperature (22±2°C) over a maximum period of 28 days. Samples were taken immediately after preparation (day 0) and after 2, 7, 14, 21, and 28 days. Physicochemical stability was determined by ion-exchange high-performance liquid chromatography (IE-HPLC) and size-exclusion high-performance liquid chromatography (SE-HPLC) with ultraviolet detection, pH measurement and visual inspection for particles or colour changes.ResultsIn the IE-HPLC assay, peak areas and peak-to-peak area ratios remained unchanged over the whole study period, and showed no additional peaks of degraded daratumumab charge variants. In the SE-HPLC assay, neither a formation of aggregates nor of fragments was detected. Daratumumab monomer concentrations exceeded 95% of the initially measured concentrations over the entire test period. pH values remained constant. Test solutions remained clear, and no colour changes or visible particles were detected. All results were independent of storage conditions.ConclusionDaratumumab subcutaneous injection solution proved to be physicochemically stable in capped three-piece plastic syringes for at least 28 days when stored light protected at 2–8°C or at room temperature (22±2°C). For microbiological reasons aseptic preparation and refrigerated storage are recommended. In-use stability of ready-to-administer daratumumab subcutaneous syringes prepared under appropriate aseptic conditions is given for 28 days.
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2023-003928
Issue No: Vol. 32, No. 2 (2025)
- Formulation and characterisation of metyrapone suppositories for the first
effective long-term use in an infant with McCune-Albright syndrome-related
Cushing syndrome-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Ratzinger-Stoeger, G; Anzengruber, M, Skoll, K, Ertl, D.-A, Hartmann, G, Gabor, F.
Pages: 161 - 165
Abstract: ObjectivesThe aim of this project was to develop a rectal formulation of metyrapone suitable for application in an infant hospitalised with McCune-Albright syndrome (MAS)-related Cushing syndrome and to provide a detailed description of the formulation protocol including quality control parameters.MethodsSuppositories with a drug load of up to 100 mg metyrapone were prepared. Mass variation, content uniformity and drug release were analysed according to the guidelines set out by the European Pharmacopoeia. Monitoring of the drug content for 6 weeks allowed for estimation of the storage stability at 2–8°C.ResultsA protocol for the reproducible preparation of suppositories with intended metyrapone content of 30–100 mg was established. The suppositories were well tolerated by the patient and the clinical outcome is promising. The suppository preparations complied with the regulations from the European Pharmacopoeia. Further, a stability of the rectal formulation of at least 1 month was confirmed, facilitating medication supply for home care.ConclusionsAn adequate and easy to follow protocol for preparation of high-quality metyrapone suppositories, with sufficient stability for practical use and fulfilling major pharmaceutical quality parameters, was established. The protocol can be easily replicated by skilled personnel in a community pharmacy facilitating treatment of the infant in home care.
Keywords:
EAHP Statement 3: Production and Compounding
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2023-003853
Issue No: Vol. 32, No. 2 (2025)
- Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in
patients with cystic fibrosis: real-life effectiveness-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Jimenez-Lozano, I; Luna-Paredes, C, Monte-Boquet, E, Fernandez-Polo, A, Canete-Ramirez, C, Roch-Santed, M, Gartner, S, Alvarez-Fernandez, A.
Pages: 166 - 171
Abstract: BackgroundInhaled antibiotics have achieved or stabilised the clinical condition of patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection. We aimed to determine the effectiveness of aztreonam lysine inhaled solution (AZLI) in patients with CF and chronic P. aeruginosa infection.MethodsA retrospective observational study was conducted on patients with CF and chronic P. aeruginosa infection who received AZLI between July 2012 and September 2018 inclusive in three Spanish hospitals in a routine clinical practice setting. The primary endpoint was the absolute change in the percentage of predicted forced expiratory volume in 1 second (FEV1) compared with the previous 12 months, at the start of AZLI treatment and 12 months after starting the drug. Other variables analysed were exacerbations, hospitalisations, type and route of antibiotics prescribed, weight and body mass index (BMI) and adverse drug reactions.ResultsIn a cohort of 52 patients, AZLI treatment led to stabilisation of FEV1, changing from a mean (SD) value of 55.60 (21.3)% at the start of treatment to 56.8 (20.4)% after 12 months of treatment (p=0.5296) in patients who had not previously received the drug. In addition, it significantly reduced exacerbations from a median (P25; P75) of 2.0 (1.0; 3.0) in the 12 months prior to AZLI to 1.0 (1.0; 2.0) in the 12 months after treatment initiation (p=0.0350). AZLI also reduced the need for other antibiotics and prevented a decrease in BMI, with an adequate safety profile.ConclusionsAZLI achieved stabilisation of lung function measured by FEV1 in patients with CF and chronic P. aeruginosa infection, along with an adequate safety profile.
Keywords:
EAHP Statement 5: Patient Safety and Quality Assurance
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2023-003937
Issue No: Vol. 32, No. 2 (2025)
- Evaluation of the impact of pharmacist-led educational intervention on
knowledge and skills of cancer patients with totally implantable venous
access port: a single-centre, non-randomised controlled study-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Nizet, P; Grivel, C, Petit, M, Chapron, P, Derouin, Y, Corbineau, E, Dumont, R, Huon, J.-F.
Pages: 172 - 177
Abstract: BackgroundTotally implantable venous access port (TIVAP) is a type of implantable medical device that enables repetitive access to the intravenous system through use of a Huber needle. This device facilitates the administration of aggressive or long-term treatments while ensuring the comfort and safety of the patient. To ensure proper use of the medical device and lower the risk of complications, it is essential that patients acquire the necessary knowledge and skills regarding TIVAP.ObjectiveThe main objective of the study was to assess the impact of a pharmaceutical interview on patients’ knowledge and skills for patients with TIVAP.MethodsTo achieve this goal, a pharmaceutical interview guide and an 18-item questionnaire were developed, based on a three-part competency framework (knowledge, know-how and attitudes) previously constructed by a multidisciplinary team. The intervention consisted of a pharmacist-led interview with every patient on the day of the TIVAP insertion. Patients in the control group received usual care. Patients included were interviewed by telephone 14 days after implantation. 2 tests were conducted to compare the scores obtained by each group.ResultsThe average score obtained by the control group (n=30) was 8.97, while the intervention group (n=59) achieved an average score of 12.66 (p
Keywords:
EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2023-003896
Issue No: Vol. 32, No. 2 (2025)
- Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world
observations of erenumab, fremanezumab and galcanezumab-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Talbot, J; Stuckey, R, Wood, N, Gordon, A, Crossingham, G, Weatherby, S.
Pages: 178 - 185
Abstract: ObjectivesThe anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP-mAb) are effective in migraine; however, few studies have examined the benefit of switching from one anti-CGRP-mAb to another. In order to better inform clinical practice in this situation, we present our real-world findings of switching anti-CGRP-mAb in chronic migraine.MethodsIndividuals with chronic migraine that switched anti-CGRP-mAb treatment (erenumab, fremanezumab or galcanezumab) due to ineffectiveness or adverse effects were retrospectively identified. Headache diary data before and up to 6 months after anti-CGRP-mAb switch were analysed. Main outcome measures were monthly red days (days with headaches limiting activity or requiring triptans), headache days (days with any kind of headache), triptan use, other analgesic use and headache disability (Headache Impact Test-6 (HIT-6) score) at 3 months.ResultsThe analysis included 66 instances of switching among 54 individuals. There were non-significant reductions of –1.2 (–2.7, 0.3) red days from baseline at 3 months, with 10 individuals (15%) showing ≥50% improvement and 22 (33%) experiencing a ≥30% improvement. Improvements in headache days, triptan days, other painkiller use and HIT-6 score were non-significant. When individuals that switched due to side effects were excluded from the analysis, significant reductions in headache (Friedman p=0.044) and a trend for improvement in red days (Friedman p=0.083) were observed. With regard to side effects, on 12 occasions these improved or resolved on switching to a different anti-CGRP-mAb, while new symptoms were reported on eight occasions following a switch.ConclusionWe recorded modest improvements in headache outcomes, although significant results were only observed in those that switched anti-CGRP-mAb due to ineffectiveness. Switching may therefore be a viable option for these individuals.
Keywords:
EAHP Statement 1: Introductory Statements and Governance
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2023-003779
Issue No: Vol. 32, No. 2 (2025)
- Infectious diseases and antimicrobial resistance
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Kuruc Poje, D; Miljkovic, N, Polidori, P, Kohl, S.
Pages: 186 - 189
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2023-003920
Issue No: Vol. 32, No. 2 (2025)
- Clinical experience with immunotherapy in patients with diffuse intrinsic
pontine glioma-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Gasanz Garicochea, M; Martinez-Romera, I, Osuna-Marco, M. P, Lopez-Ibor Alino, B.
Pages: 190 - 192
Abstract: The objective of the article is to report the case of three patients with diffuse intrinsic pontine glioma (DIPG) treated with immunotherapy. In particular we report the data related to the treatments’ efficacy and tolerance.To achieve this, we review the medical records in the Paediatric Oncology and Haematology Unit of HM Hospitales/Centro Integral Oncológico Clara Campal (CIOCC). We focused on patients diagnosed with DIPG who were administered oncolytic viruses followed by immune checkpoint inhibitors (ICI) (pembrolizumab, anti PD-1) plus a concomitant antiangiogenic agent (bevacizumab).The results we obtained showed the three paediatric DIPG patients studied presented good tolerance, with disease stabilisation for approximately 5 months after immunotherapy. However, subsequent clinical worsening required clinicians to change the patients’ treatment.In conclusion, immunotherapy combined with other conventional antineoplastic treatments (chemotherapy, radiotherapy) is postulated as a very promising future therapeutic option. However, further research is warranted in the paediatric population to demonstrate safety and effectiveness.
Keywords:
EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2022-003511
Issue No: Vol. 32, No. 2 (2025)
- Assessment of particle contamination in vancomycin syringe pumps following
fluid withdrawal using three diverse aseptic reconstitution techniques-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
van den Berg, R. B; van Bommel, M. M, Stoker, L. J, Westerman, E. M.
Pages: 193 - 193
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2024-004214
Issue No: Vol. 32, No. 2 (2025)
- HMGCR-associated myopathy in polymorbid patients with polypharmacy should
not be attributed solely to statins-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Finsterer; J.
Pages: 194 - 195
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2024-004253
Issue No: Vol. 32, No. 2 (2025)
- Potential risk of non-arteritic anterior ischaemic optic neuropathy in
semaglutide users: pharmacovigilance insights-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Castellana; E.
Pages: 194 - 194
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2024-004333
Issue No: Vol. 32, No. 2 (2025)
- Correspondence on: 'Patient reported medication-related problems,
adherence and waste of oral anticancer medication over time by van den
Bemt et al-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Cao, J; Chen, Z, Xu, F.
Pages: 195 - 196
PubDate: 2025-02-21T00:45:41-08:00
DOI: 10.1136/ejhpharm-2024-004424
Issue No: Vol. 32, No. 2 (2025)
|
Hybrid journal (It can contain Open Access articles)
